IQVIA Holdings: Q2 Earnings Insights

Shares of IQVIA Holdings IQV fell 1.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 22.88% over the past year to $1.18, which beat the estimate of $1.06.

Revenue of $2,521,000,000 declined by 7.99% from the same period last year, which beat the estimate of $2,410,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $6.10 and $6.30.

The upcoming fiscal year's revenue expected to be between $11,000,000,000 and $11,100,000,000.

How To Listen To The Conference Call

Date: Jul 22, 2020

Time: 09:00 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.iqvia.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2395789&sessionid=1&key=C8C68C988BD54CBEAF0A22ED2AA35A7E&regTag=&sourcepage=register

Technicals

Company's 52-week high was at $169.14

Company's 52-week low was at $81.79

Price action over last quarter: Up 9.68%

Company Description

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The CRO segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The legacy IMS business provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.